Education
About Us
Working with TipRanks
Follow Us
Immunovia AB (SE:IMMNOV)
:IMMNOV
IMMNOV Stock Chart & Stats
kr0.23
-kr0.02(-4.98%)
At close: 4:00 PM EST
kr0.23
-kr0.02(-4.98%)
Day’s Range― - ―
52-Week Rangekr0.16 - kr0.75
Previous CloseN/A
Volume868.16K
Average Volume (3M)5.10M
Market Cap
kr118.93M
Enterprise Valuekr47.12M
Total Cash (Recent Filing)kr26.57M
Total Debt (Recent Filing)kr20.37M
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Feb 24, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding672,666,900
10 Day Avg. Volume6,199,351
30 Day Avg. Volume5,096,607
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.01
Price to Sales (P/S)37.67
P/FCF Ratio-0.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Launch And KOL AdoptionEarly adoption by ten leading pancreatic cancer centers signals strong clinician advocacy and clinical validation. Sustained KOL support can drive referrals, trial enrollment, and replication across specialist networks, accelerating durable commercial uptake and credibility over several months.
Medicare Reimbursement Rate EstablishedA defined Medicare CLFS rate of $897 creates a durable price precedent in the U.S., easing payer discussions and providing a concrete revenue-per-test benchmark. This structural reimbursement recognition materially improves prospects for scalable commercial revenue and pricing stability over time.
Reduced Cash Burn And New CapitalLower monthly cash burn plus a >SEK100m capital raise meaningfully extend operational runway. This improves the company's ability to execute a phased commercial rollout, pursue reimbursement and partnership talks, and reduces near-term refinancing pressure while scaling commercialization efforts.
Bears Say
Small, Declining Revenue BaseTTM revenue is small and falling (~14.6% decline), with Q3 net sales minimal. A shrinking, low revenue base undermines scalability and internal funding capacity, delays path to break-even, and heightens dependence on external financing for commercial expansion over the medium term.
Negative Stockholders' EquityNegative stockholders' equity signals materially weakened balance-sheet strength. Persistent losses and negative equity constrain borrowing capacity, elevate dilution risk from future financings, and can hinder partnership or distribution agreements that favor financially robust counterparts.
Uncertain Payer Coverage And TimingDespite a Medicare rate, formal payer coverage is lacking, leaving reimbursement and predictable test volumes uncertain. Without broad coverage decisions, adoption and lab-level scale are likely to be delayed, slowing reliable revenue growth and making commercial forecasts structurally uncertain.
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.16 and its highest was kr0.75 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr118.93M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Feb 24, 2026 which is tomorrow.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Nov 26, 2025. The company reported -kr0.078 earnings per share for the quarter, missing the consensus estimate of -kr0.047 by -kr0.031.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.04.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.078 in its last earnings report, missing expectations of -kr0.047. Following the earnings report the stock price went up 7.813%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMNOV Company Deck
IMMNOV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reveals significant progress in Immunovia's commercial transition and positive initial market response to PancreaSure, alongside key milestones in reimbursement rate setting. However, uncertainties remain regarding coverage and revenue timelines.View all SE:IMMNOV earnings summariesTechnical Analysis
Alligator Bioscience AB
―
Prostatype Genomics AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―